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AbstrACt
Introduction Obstructive sleep apnoea (OSA) is caused 
by complete or partial obstruction of the upper airway 
resulting in repeated episodes of interrupted or shallow 
breaths. OSA is associated with significant morbidity and 
mortality. The prevalence is estimated to range from 3% 
to 7% in the general population but may be much higher. 
Several studies show that weight loss or bariatric surgery 
may have a role in treating OSA. The aim of this systematic 
review is to assess the safety and efficacy of randomised 
controlled trials (RCTs) of weight loss surgery for adults 
with OSA and comorbid obesity.
Methods and analysis A search of the Cochrane Central 
Register of Controlled Trials, PubMed, EMBASE and two 
major Chinese biomedical databases will be performed 
to identify related trials published as of October 2018. 
This study will include RCTs, comparing different types 
of weight loss surgery for OSA with obesity or weight 
loss surgery for OSA with obesity with other upper airway 
surgeries. The primary outcomes that will be measured 
are apnoea–hypopnoea index, excess weight loss and 
in-hospital mortality. The secondary outcomes will 
include duration of hospital stay, neck circumference, 
reoperation, waist circumference, body mass index, 
Epworth Sleepiness Scale score, overt complications 
(eg, gastric fistula, bleeding, delayed gastric emptying, 
wound infection), quality of life, quality of sleep and/or 
functionality. The systematic review will be conducted 
according to the recommendations as outlined by the 
Cochrane collaboration.
Ethics and dissemination The systematic review and 
meta-analysis will include published data available online 
and thus ethics approval will not be required. The findings 
will be disseminated and published in a peer-reviewed 
journal. Review updates will be conducted if there is 
new evidence that may cause any change in review 
conclusions. Any changes to the study protocol will be 
updated in the PROSPERO trial registry accordingly.
PrOsPErO registration number CRD42017081743.
IntrOduCtIOn 
description of the condition
Obstructive sleep apnoea (OSA) is caused by 
complete or partial obstruction of the upper 
airway that results in repeated episodes of 
interrupted or shallow breaths. Repeated 
apnoea and hypopnoea at night cause inter-
mittent hypoxia, hypercapnia, sympathetic 
nerve excitability, enhanced systemic inflam-
matory response and oxidative stress and 
antioxidant capacity.1 OSA results in sleep 
deficits, daytime napping, fatigue, arrhyth-
mias, electroencephalographic arousal, 
daytime hypertension and acute intermit-
tent surges in blood pressure at night, coro-
nary heart disease, diabetes, cerebrovascular 
diseases, traffic accidents and even sudden 
death at night.2–4 OSA is associated with 
significant morbidity and mortality, including 
cardiovascular mortality.5 The prevalence 
of OSA accompanied by daytime sleepiness 
is estimated to range from 3% to 7% in 
the general population and possibly much 
higher.6 7 It occurs throughout the world with 
about equal frequency, in both developed 
strengths and limitations of this study
 ► This will be the first systematic review and me-
ta-analysis to assess the safety and efficacy of
weight loss surgery for  obstructive sleep apnoea
(OSA) with obesity in adults, and this study will in-
clude studies comparing various types of bariatric
surgery or various other upper airway surgeries for
OSA.
 ► This study will comprehensively evaluate the ap-
noea–hypopnoea index , excess weight loss,
in-hospital mortality, duration of hospital stay, neck
circumference, reoperation, waist circumference,
body mass index, Epworth Sleepiness Scale ques-
tionnaire, overt complications, quality of life, quality
of sleep and functionality.
 ► A lack of sufficient high-quality randomised con-
trolled trials will limit the findings of the study be-
cause of the need to then include non-randomised
or observational studies.
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and developing countries.5–8 OSA can result in damage to 
multiple organs and systems.9–12 
The major risk factors for OSA are obesity, age, gender, 
anatomical abnormalities of the upper airway anatomy, 
a family history of OSA syndrome, long-term heavy 
drinking, use of sedative-hypnotics or muscle relaxation 
drugs and long-term smoking.13 Other minor risk factors 
include hypothyroidism, acromegaly, cardiac insuffi-
ciency, stroke, gastro-oesophageal reflux and neuromus-
cular diseases.14 15
description of the intervention
Usually, OSA may be treated with lifestyle modification, 
external therapies to keep the airway open while sleeping 
(positive airway pressure, mouthpiece), or surgery or 
other procedures (surgical removal of tissue, upper 
airway stimulation, jaw surgery, surgical opening in the 
neck, implants).16 17 Moreover, evidence shows that weight 
loss could reduce apnoea–hypopnoea index (AHI) and 
improve the symptoms of apnoea in obese patients with 
OSA.18 19 Weight loss surgery also called ‘bariatric surgery’ 
includes gastric bypass surgery, sleeve gastrectomy, adjust-
able gastric banding surgery, biliopancreatic diversion 
and a few more infrequently used procedures.
A systematic review showed that weight loss surgery 
improved weight loss outcomes more than non-surgical 
interventions.20 By addressing the major risk factors for 
OSA, weight loss surgery may have a role in treating or 
curing OSA. In 36 of 54 patients with a preoperative diag-
nosis of OSA (24 women, median age 38 years, range 
23–56 years), De Genio et al reported that after subse-
quent sleeve gastrectomy, there were decreases in weight 
(p=0.001), body mass index (BMI) (p=0.001), decreased 
excess weight (p=0.001), decreased neck circumference 
(p=0.001) and decreased fat mass (p=0.001) after 5 years 
of follow-up; 29 (80.6%) patients recovered or were 
‘cured’ of OSA syndrome (AHI improved to <5).21 In 
2016, a prospective cohort study on 59 morbidly obese 
patients reported that laparoscopic sleeve gastrectomy 
led to rapid weight loss and improved OSA symptoms at 
6 months postoperatively.22 A review of 69 studies with 
13 900 patients indicated that all the procedures (Roux-
en-Y gastric bypass, sleeve gastrectomy, biliopancreatic 
diversion) achieved profound effects on OSA, as over 
75% of patients had improvement in their sleep apnoea 
symptoms.23 Laparoscopic adjustable gastric banding 
was the worst procedure in improving or resolving OSA, 
and biliopancreatic diversion was the most successful 
procedure. The 2014 clinical practice guidelines for 
bariatric surgery strongly recommend that obese persons 
(BMI >30 kg/m2) with OSA be encouraged to lose weight 
(strong recommendation, but low-quality evidence).24
How the intervention might work
In OSA, gravity and muscle relaxation allows the tongue 
and surrounding soft tissues to fall posteriorly into 
the throat, thereby obstructing the airflow. Repeated 
episodes of complete or partial blockage of the upper 
airway during sleep results in OSA. Subsequently, the 
diaphragm and chest muscles work harder by trying to 
open the airway, and breathing usually resumes with a 
loud gasp,14  snort or body jerk. These episodes often 
interfere with sleep quality and can reduce the flow of 
oxygen to vital organs, causing irregularities in heart 
rhythm.25 26 Obesity can lead to accumulation of neck fat, 
increasing neck circumference and mass loading on the 
pharynx, thus decreasing the cross-sectional area of the 
pharynx leading to collapse of the pharynx and subse-
quent OSA.27 28 Therefore, weight loss may relieve the 
symptoms of OSA by changing fat distribution, reducing 
neck circumference and widening the narrow airway 
formed by the soft tissue of the tongue and throat. The 
role of weight loss surgery for OSA with obesity in adults 
for OSA may also have some association with endocrine 
and metabolic function, as well as neuromuscular struc-
ture and function.29
Why it is important to do this review
The role of weight loss surgery for OSA with obesity 
in adults in treating OSA is largely uncertain. There is 
insufficient evidence to inform clinical guidelines, and 
this topic remains controversial in the medical commu-
nity. Our preliminary research confirmed that obesity is 
an important risk factor for OSA. It will be interesting 
to see whether an intervention targeted towards obesity 
can improve OSA and help to guide clinical practice 
for patients who are unable to lose weight from lifestyle 
modification alone.
ObjECtIvEs
The aim is to conduct a systematic review and meta-anal-
ysis of studies to assess the efficacy and safety of weight 
loss surgery for OSA with obesity in adults (comparing 
one type of weight loss surgery for OSA with obesity 
in adults with another for OSA, comparing weight loss 
surgery for OSA with obesity in adults with various other 
upper airway surgeries) in the treatment of OSA in 
adults.
MEtHOds
Criteria for considering studies for this review
Types of studies
We will include all randomised controlled trials (RCTs) 
(irrespective of blinding, publication status, language 
or publication date), including those that assessed OSA 
before and after the intervention. We plan to exclude 
observational and non-randomised controlled studies 
unless there are insufficient data from RCTs. We will 
include studies reported in full text, and those published 
as an abstract only, in which case we will email the 
researcher for the data if the study is complete but not 
yet published.
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Types of participants
We will include studies of adult patients (≥18 years old) 
who are obese or overweight (BMI >25 kg/m2), and who 
have undergone weight loss surgery for OSA. We will 
exclude studies of patients with obesity without OSA, or 
with severe comorbidities who cannot undergo surgery.
Types of interventions
We will include studies comparing any type of weight loss 
surgery with another for OSA. Weight loss surgery in our 
study is defined as the following procedures: laparoscopic 
Roux-en Y gastric bypass, laparoscopic sleeve gastrectomy, 
laparoscopic adjustable gastric banding, laparoscopic 
biliopancreatic diversion with duodenal switch and other 
similar procedures. We will include studies comparing 
weight loss surgery with otorhinolaryngology surgeries or 
oral and maxillofacial surgeries. We will perform a sensi-
tivity analysis combining only studies with low risk of bias.
Types of outcome measures
Primary outcomes
1. AHI (the change in AHI from before to after weight
loss surgery, none/minimal: AHI <5 per hour; mild:
AHI ≥5, but <15 per hour; moderate: AHI ≥15, but <30
per hour; severe: AHI ≥30 per hour).30
2. Excess weight loss (EWL).31
3. In-hospital mortality.
Secondary outcomes
1. Duration of hospital stay (days).
2. Neck circumference.
3. Reoperation (reoperation due to serious complica-
tions or recovery of obesity or OSA within 3–5 years).
4. Waist circumference.
5. BMI.
6. Epworth Sleepiness Scale questionnaire (http:// epwo
rths leep ines sscale. com/ about- the- ess/).
7. Overt complications (eg, gastric fistula, bleeding, de-
layed gastric emptying, wound infection).32
8. Quality of life33 and quality of sleep.34 The outcomes
will be measured at 1 week, 1 month, 3 months,
6 months, 1 year, 2 years and 3 years after surgery.
search methods for identification of studies
Electronic searches
We will identify trials from searches of the following 
databases:
1. Cochrane Airways Trials Register (Cochrane Register
of Studies); inception to October 2018.
2. Cochrane Central Register of Controlled Trials, latest
issue (Cochrane Library).
3. MEDLINE (Ovid) 1946 to October 2018.
4. EMBASE (Ovid) 1974 to October 2018.
5. Web of Science all years to October 2018.
We will search the following trials registries:
1. US National Institutes of Health Ongoing Trials
Register  ClinicalTrials. gov (https://www. clinicaltrials. 
gov/).
2. WHO International Clinical Trials Registry Platform
(http:// apps. who. int/ trialsearch/).
3. Australian New Zealand Clinical Trials Registry
(http://www. anzctr. org. au/).
4. International Standard Randomized Controlled Tri-
al Number Register (http://www. isrctn. org/) OR
(http://www. controlled- trials. com/).
5. Chinese Clinical Trial Register (http://www. chictr. org.
cn/).
6. Trials Central (www. trialscentral. org/).
We will search all sources from inception to October
2018, with no restriction on language of publication.
Other resources
We will check the reference lists of all primary studies and 
review articles for additional potentially relevant refer-
ences. We will search relevant manufacturers' websites for 
study information. We will search for errata or retractions 
from included studies published in full text on PubMed 
(www. ncbi. nlm. nih. gov/ pubmed) and report the date of 
publication.
search strategy
The study search strategy is presented in online supple-
mentary appendix 1. This will be appropriately adapted 
for use in the other databases.
data collection and analysis
Selection of studies
Two review authors (ZYD, BYH) will screen the titles 
and abstracts of the search results independently and 
code them as 'retrieve' (eligible or potentially eligible/
unclear) or 'do not retrieve'. We will retrieve the full-text 
study reports of all potentially eligible studies and two 
review authors (ZYD, BYH) will independently screen 
them for inclusion, recording the reasons for exclusion 
if ineligible. We will resolve any disagreement through 
discussion or, if required, we will consult a third review 
author (CCW). We will identify and exclude duplicates 
and collate multiple reports of the same study so that 
each study, rather than each report, is the unit of interest 
in the review. We will record the selection process in suffi-
cient detail to complete a Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses flow diagram and a 
'characteristics of excluded studies’ table.35
Data extraction and management
For study characteristics and outcome data, we will use a 
data collection form, which has been piloted on at least 
one study in the review. Two review authors (AMY, ZYD) 
will extract and record the following study characteristics:
1. Methods: study design, total duration of study, details
of any 'run-in' period, number of study centres and lo-
cation, study setting, withdrawals and date of study.
2. Participants: number of study participants, mean age,
age range, gender, severity of condition, diagnostic
criteria, baseline lung function, smoking history, inclu-
sion criteria and exclusion criteria.
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3. Interventions: intervention, comparison, concomitant
medications and excluded medications.
4. Outcomes: primary and secondary outcomes specified
and collected, and time points reported.
5. Notes: funding for studies and notable conflicts of in-
terest of trial authors.
Two review authors (ZYD, BYH) will independently
extract outcome data. If outcome data are not reported 
in a usable way, we will note that in the 'characteristics 
of included studies’ table. We will resolve disagreements 
by consensus. If disagreements cannot be resolved by 
consensus, we will seek an opinion from a third review 
author (CCW). One review author (ZYD) will transfer 
data into the Review Manager file.36 We will double check 
that data are entered correctly by comparing the data 
presented in the systematic review with the study reports. 
A second review author (AMY) will spot-check study char-
acteristics for accuracy against the study report.
Assessment of risk of bias in included studies
Three review authors (ZYD, BYH, AMY) will independently 
assess risk of bias for each study using the criteria outlined 
in the Cochrane Handbook for Systematic Reviews of 
Interventions.37 We will resolve any disagreements by 
discussion or by involving another author (CCW). We will 
assess the risk of bias according to the following domains:
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We will judge each potential source of bias as high, low
or unclear and provide a quote from the study report 
together with a justification for our judgement in the ‘risk 
of bias’ table. We will summarise the risk of bias judge-
ments across different studies for each of the domains 
listed. We will consider blinding separately for different 
key outcomes where necessary (eg, for unblinded outcome 
assessment, risk of bias for all-cause mortality may be very 
different than for a patient-reported pain scale). Where 
information on risk of bias relates to unpublished data 
or correspondence with a trialist, we will note this in the 
'risk of bias' table. When considering treatment effects, 
we will take into account the risk of bias for the studies 
that contribute to that outcome.
Assessment of bias in conducting the systematic review
We will conduct the review according to this published 
protocol and justify any deviations from it in the 'differ-
ences between protocol and review' section of the system-
atic review.
Measures of treatment effect
We will analyse dichotomous data as OR and contin-
uous data as the mean difference (MD) or standardised 
mean difference (SMD). If data from rating scales are 
combined in a meta-analysis, we will ensure they are 
entered with a consistent direction of effect. We will 
undertake meta-analyses only if a potentially meaningful 
result may be obtained. That is, if the treatments, partic-
ipants and the underlying clinical question are similar 
enough for pooling to be appropriate. We will describe 
skewed data as medians and IQRs for each group. Where 
multiple trial arms are reported in a single study, we will 
include only the relevant arms. If two comparisons (eg, 
procedure A vs procedure C and procedure B vs proce-
dure C) are combined in the same meta-analysis, we will 
either combine the active arms or halve the control group 
to avoid double counting. If adjusted analyses are avail-
able, we will use these as a preference in our meta-anal-
yses. We will consider the data from each study according 
to the intention-to-treat principle.
Unit of analysis issues
We will use participants, rather than events, as the unit 
of analysis for dichotomous outcomes. We anticipate no 
unit of analysis issues. However, if rate ratios are reported 
in a study, we will analyse them on this basis. We will 
only perform a meta-analysis on data from cluster RCTs, 
if the available data can be adjusted to account for the 
clustering.
Dealing with missing data
All necessary data will be extracted from the included 
trials. We will contact the authors of the primary studies 
to request missing data if necessary. Where this is not 
possible, and the missing data are thought to introduce 
serious bias, we will take this into consideration in the 
Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) rating for affected outcomes.
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among 
the studies in each analysis. If we identify substantial 
heterogeneity, we will report it and explore the possible 
causes by conducting a prespecified subgroup analysis.
Assessment of reporting biases
If we are able to pool more than 10 studies, we will create 
and examine a funnel plot to explore possible small study 
and publication biases. We only plan to use funnel plots 
if the number of included studies is ≥10. We will use the 
Begg and Egger tests if we have less than 10 included 
studies.38 39
Data synthesis
We will perform the data analysis using the meta-analysis 
software RevMan V.5.3. We will use a random-effects model 
for all analyses. The extracted data will be combined by 
calculating a pooled estimate of the risk ratio and 95% CI 
for dichotomous data. The weighted MD and 95% CI will 
be calculated for continuous data.37 The SMD will be 
used as a summary statistic in this systematic review, when 
the studies all assess the same outcome but measure it in 
a variety of ways.
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‘Summary of findings’ table
We will create a ‘summary of findings’ table using the 
following outcomes: AHI; EWL; in-hospital mortality; 
reoperation; overt complications (eg, gastric fistula, 
bleeding, delayed gastric emptying, wound infection); 
quality of life and excessive daytime sleepiness. We will 
use the five GRADE considerations (risk of bias, consis-
tency of effect, imprecision, indirectness and publica-
tion bias) to assess the quality of a body of evidence as it 
relates to studies that contribute data for the prespecified 
outcomes.40 We will use the methods and recommen-
dations described in section 8.5 and chapter 12 of the 
Cochrane Handbook for Systematic Reviews of Interven-
tions,37 using GRADEpro software.40 We will explain justi-
fications for decisions to downgrade the quality of studies 
in footnotes where we will also add comments to aid the 
reader's understanding of the review, where necessary.
Subgroup analysis and investigation of heterogeneity
If the available evidence allows, we intend to perform the 
following subgroup analyses:
1. Different bariatric surgical procedures (laparoscopic
Roux-en Y gastric bypass vs laparoscopic sleeve gastrec-
tomy and other types of bariatric surgery for OSA).
2. Middle-aged patients versus elderly patients (≥65 years
old).
3. Obese versus overweight patients.
We will use the following outcomes in subgroup
analyses:
1. Participants with mild OSA versus those with moderate
OSA or severe OSA.
2. Participants with BMI >50 kg/m2 versus participants
with BMI ≤50 kg/m2.
We will use Review Manager V.5.3 for the analyses.
Sensitivity analysis and subgroup analyses
We will perform sensitivity analyses to explore the influ-
ence of different study-related characteristics on the 
effect size. Our planned sensitivity analyses include re-es-
timating the combined effect size after analysis of:
1. Studies with low risk of bias versus studies with high
risk of bias.
2. Removing studies with either small sample sizes.
Changes in results and/or the conclusions following
a sensitivity analysis would indicate a lack of robustness 
in the study findings. We will compare the results from a 
fixed-effect model with a random-effects model.37
Patient involvement
Patient involvement was not considered in writing this 
protocol as we were unaware of the requirement, but we 
intend to reconsider and seek advice on how we might 
seek input from patients at this stage.
dIsCussIOn
In an unpublished meta-analysis of 11 case-control studies, 
we found that BMI was significantly associated with an 
increased risk of OSA in children (p<0.00001) and adults 
(p<0.002). Young et al reported that men had a four times 
higher risk of sleep-disordered breathing (polysomno-
graphically defined AHI of five or higher) for each SD 
increase in BMI.41 These and other studies support our 
hypothesis that weight loss surgery can improve weight 
loss outcomes, and may have a role in treating or curing 
OSA.19–22 However, currently, there is no meta-analysis 
to confirm this hypothesis, and this study will be the first 
systematic review and meta-analysis to assess the safety 
and efficacy of weight loss surgery for OSA with obesity in 
adults. The results of this study will help to enhance the 
evidence for weight loss surgery performed for patients 
with OSA and comorbid obesity.
Ethics and dissemination
The systematic review and meta-analysis will include 
published data available online. The findings will be 
disseminated and published in a peer-reviewed journal. 
Review updates will be conducted if there is new evidence 
that may cause any change in review conclusions. Any 
changes to the study protocol will be updated in the 
PROSPERO trial registry accordingly.
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